After finishing at $8.63 in the prior trading day, Abeona Therapeutics Inc (NASDAQ: ABEO) closed at $6.99, down -19.00%. In other words, the price has decreased by -$1.64 from its previous closing price. On the day, 1397311 shares were traded.
Ratios:
Our goal is to gain a better understanding of ABEO by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 6.81 and its Current Ratio is at 6.81. In the meantime, Its Debt-to-Equity ratio is 0.26 whereas as Long-Term Debt/Eq ratio is at 0.18.
On September 18, 2020, B. Riley FBR started tracking the stock assigning a Buy rating and target price of $5.
On February 10, 2020, SVB Leerink started tracking the stock assigning a Outperform rating and target price of $6.SVB Leerink initiated its Outperform rating on February 10, 2020, with a $6 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Feb 06 ’24 when Seshadri Vishwas bought 20,000 shares for $4.39 per share. The transaction valued at 87,800 led to the insider holds 528,260 shares of the business.
Alvino Mark sold 7,084 shares of ABEO for $36,199 on Jan 17 ’24. The Director now owns 62,816 shares after completing the transaction at $5.11 per share. On Sep 27 ’23, another insider, Seshadri Vishwas, who serves as the Chief Executive Officer of the company, bought 20,000 shares for $4.07 each. As a result, the insider paid 81,400 and bolstered with 521,731 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ABEO now has a Market Capitalization of 185.53M and an Enterprise Value of 138.71M. For the stock, the TTM Price-to-Sale (P/S) ratio is 48.50 while its Price-to-Book (P/B) ratio in mrq is 7.84. Its current Enterprise Value per Revenue stands at 38.88 whereas that against EBITDA is -3.40.
Stock Price History:
Over the past 52 weeks, ABEO has reached a high of $9.01, while it has fallen to a 52-week low of $2.24. The 50-Day Moving Average of the stock is 6.20, while the 200-Day Moving Average is calculated to be 4.67.
Shares Statistics:
The stock has traded on average 326.61K shares per day over the past 3-months and 478.94k shares per day over the last 10 days, according to various share statistics. A total of 24.77M shares are outstanding, with a floating share count of 23.32M. Insiders hold about 5.85% of the company’s shares, while institutions hold 66.72% stake in the company. Shares short for ABEO as of Feb 29, 2024 were 1.64M with a Short Ratio of 5.03, compared to 778.47k on Jan 31, 2024. Therefore, it implies a Short% of Shares Outstanding of 6.63% and a Short% of Float of 7.30%.
Earnings Estimates
Its stock is currently analyzed by 4 different market analysts. On average, analysts expect EPS of -$0.47 for the current quarter, with a high estimate of -$0.4 and a low estimate of -$0.51, while EPS last year was $1.53. The consensus estimate for the next quarter is -$0.51, with high estimates of -$0.45 and low estimates of -$0.58.
Analysts are recommending an EPS of between -$1.94 and -$2.38 for the fiscal current year, implying an average EPS of -$2.23. EPS for the following year is -$1.71, with 4 analysts recommending between -$1.55 and -$1.99.
Revenue Estimates
A total of 4 analysts have provided revenue estimates for ABEO’s current fiscal year. The highest revenue estimate was $3.5M, while the lowest revenue estimate was $3.5M, resulting in an average revenue estimate of $3.5M. In the same quarter a year ago, actual revenue was $1.41M, up 147.50% from the average estimate. Based on 4 analysts’ estimates, the company’s revenue will be $13.57M in the next fiscal year. The high estimate is $19.7M and the low estimate is $7.57M. The average revenue growth estimate for next year is up 287.70% from the average revenue estimate for this year.
